A trial of KTE-C19 for the treatment of chronic lymphocytic leukaemia
Phase of Trial: Phase I/II
Latest Information Update: 19 Oct 2016
At a glance
- Drugs Axicabtagene ciloleucel (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms ZUMA-8
- 19 Oct 2016 According to a Kite Pharma media release, this trial is expected to enroll the first patient in 2017.
- 19 Oct 2016 Planned initiation date changed from 1 May 2015 to 1 Jan 2017, as reported by a Kite Pharma media release.
- 02 Apr 2015 New trial record